Bal Pharma Ltd.

₹75.21

0.1 (0.2%)

BALPHARMA Share Price

Pharmaceuticals & Biotechnology

As on February 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 120 Cr

P/E Ratio16.6

Dividend Yield0.16 %

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	72.51	Bullish
10-DMA	70.8	Bullish
20-DMA	69.78	Bullish
50-DMA	71.66	Bullish
100-DMA	76.26	Bearish
200-DMA	86.28	Bearish

Historical Performance

1 Year

-25.9%

3 Years

-5.5%

5 Years

31.4%

10 Years

-15.8%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	3,031	3,392	3,042	2,812	2,505
Total Expenditure	2,733	3,083	2,790	2,572	2,259
Other Income	22	28	9	52	11
Operating Profit	320	338	262	291	258
Interest	171	147	123	109	122
Depreciation	98	101	91	90	95
Profit Before Tax	51	90	47	92	41
Consolidated Net Profit	72	74	26	56	47
Adjusted EPS	5	5	2	4	3

Compounded Sales Growth

10 Years:8.9

5 Years:12.1

3 Years:1.5

TTM:-2.2

Compounded Profit Growth

10 Years:38.7

5 Years:-27.2

3 Years:5.2

TTM:-0.5

Stock Price CAGR

10 Years:-1.7

5 Years:5.6

3 Years:-0.7

TTM:-22.4

Return on Equity

10 Years:1.1

5 Years:3.2

3 Years:1.6

last year:4.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	159	158	157	148	148
Total Reserves	615	562	481	429	378
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	384	448	380	364	342
Other Current Liabilities	293	267	311	242	236
Short Term Borrowings	1,073	958	927	707	808
Total Liabilities	3,353	3,198	3,110	2,605	2,401
Capital Work in Progress	28	5	---	16	---
Long Term Loans & Advances	64	52	46	50	49
Currents Investments	25	68	---	---	---
Short Term Loans and Advances	229	221	248	170	280
Total Current Assets	2,349	2,342	2,282	1,846	1,641
Total Assets	3,353	3,198	3,110	2,605	2,401
Adjusted Book Value	49	46	41	39	36

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 16.6, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -0.7%, indicating poor shareholder returns.
The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹320 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹3031 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 776080.9

No. of Shares: 10319 (Approx)

Performance:-22.4%

P/L: ₹-223919.1

NIFTY Performance: 11.1%

1 day Top Gainers